Literature DB >> 19834767

Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study.

Mauro Signorelli1, Andrea Alberto Lissoni, Gennaro Cormio, Dionyssios Katsaros, Antonio Pellegrino, Luigi Selvaggi, Fabio Ghezzi, Giovanni Scambia, Paolo Zola, Roberto Grassi, Rodolfo Milani, Raffaella Giannice, Giovanna Caspani, Costantino Mangioni, Irene Floriani, Eliana Rulli, Roldano Fossati.   

Abstract

BACKGROUND: Five percent to 20% of stage I endometrial cancer patients undergoing total abdominal hysterectomy and bilateral salpingo-oophorectomy develop vaginal and pelvic recurrences. Adjuvant radiotherapy can improve locoregional control but not survival. This randomized trial aimed to determine whether a modified radical (Piver-Rutledge class II) hysterectomy can improve survival and locoregional control compared to the standard extrafascial (Piver-Rutledge class I) hysterectomy.
METHODS: Eligible patients (n = 520) with stage I endometrial cancer were randomized to class I or class II hysterectomy. Primary endpoint was overall survival.
RESULTS: The median length of parametria and vagina removed were 15 and 5 vs. 20 mm and 15 mm for class I and class II hysterectomy, respectively (P > 0.001). Operating time and blood loss were statistically significantly higher for class II hysterectomy. At a median follow-up of 70 months, 51 patients had died. Five-year disease-free and overall survival were similar between arms (87.7 and 88.9% in the class I arm and 89.7 and 92.2% in the class II arm, respectively). The unadjusted hazard ratios for recurrence was 0.91 (95% confidence interval, 0.55-1.51, P = 0.72), and the hazard ratio for death was 0.77 (95% confidence interval, 0.44-1.33, P = 0.35).
CONCLUSIONS: Class II hysterectomy did not improve locoregional control and survival compared to class I hysterectomy, but when an adequate vaginal cuff transection is not feasible with class I hysterectomy, a modified radical hysterectomy allows to obtain an optimal vaginal and pelvic control of disease with a minimal increase in surgical morbidity.

Entities:  

Mesh:

Year:  2009        PMID: 19834767     DOI: 10.1245/s10434-009-0736-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.

Authors:  Thomas Hogberg; Mauro Signorelli; Carlos Freire de Oliveira; Roldano Fossati; Andrea Alberto Lissoni; Bengt Sorbe; Håkan Andersson; Seija Grenman; Caroline Lundgren; Per Rosenberg; Karin Boman; Bengt Tholander; Giovanni Scambia; Nicholas Reed; Gennaro Cormio; Germana Tognon; Jackie Clarke; Tomasz Sawicki; Paolo Zola; Gunnar Kristensen
Journal:  Eur J Cancer       Date:  2010-07-07       Impact factor: 9.162

2.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

3.  Prospective Multicenter Trial Assessing the Impact of Positive Peritoneal Cytology Conversion on Oncological Outcome in Patients with Endometrial Cancer Undergoing Minimally Invasive Surgery with the use of an Intrauterine Manipulator : Positive Peritoneal Cytology Conversion and Its Association with Oncological Outcome in Endometrial Cancer.

Authors:  Franziska Siegenthaler; Silke Johann; Sara Imboden; Nicolas Samartzis; Haiyan Ledermann-Liu; Dimitri Sarlos; Markus Eberhard; Michael D Mueller
Journal:  Ann Surg Oncol       Date:  2022-09-04       Impact factor: 4.339

4.  Does the extension of the type of hysterectomy contribute to the local control of endometrial cancer?

Authors:  Tetsuya Hasegawa; Megumi Furugori; Kazumi Kubota; Mikiko Asai-Sato; Aiko Yashiro-Kawano; Hisamori Kato; Yuka Oi; Hiroyuki Shigeta; Keiko Segawa; Masakazu Kitagawa; Yuko Mine; Haruya Saji; Reiko Numazaki; Yasuyo Maruyama; Emi Ohnuma; Hanako Taniguchi; Ken Sugiura; Etsuko Miyagi; Tatsuya Matsunaga
Journal:  Int J Clin Oncol       Date:  2019-05-08       Impact factor: 3.402

5.  Prognostic Role of the Removed Vaginal Cuff and Its Correlation with L1CAM in Low-Risk Endometrial Adenocarcinoma.

Authors:  Enrico Vizza; Valentina Bruno; Giuseppe Cutillo; Emanuela Mancini; Isabella Sperduti; Lodovico Patrizi; Camilla Certelli; Ashanti Zampa; Andrea Giannini; Giacomo Corrado
Journal:  Cancers (Basel)       Date:  2021-12-22       Impact factor: 6.639

6.  Safety of total laparoscopic modified radical hysterectomy with or without lymphadenectomy for endometrial cancer.

Authors:  Masakazu Kitagawa; Kayo Katayama; Atsuko Furuno; Yukiko Okada; Asuna Yumori; Hideya Sakakibara; Hiroyuki Shigeta; Hiroshi Yoshida
Journal:  Gynecol Minim Invasive Ther       Date:  2016-05-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.